Skip to content
Arvinas logo
Search
Close
Arvinas logo
Search
Close

Publication Year: 2017

Identification of Oral Estrogen Receptor PROTAC® Degraders for Breast Cancer

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Lessons in PROTAC® Design from Selective Degradation with a Promiscuous Warhead

BET protein proteolysis targeting chimera (PROTAC®) exerts potent lethal activity against mantle cell lymphoma cells

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs®) of TANK-Binding Kinase 1

An Oral Androgen Receptor PROTAC® Degrader for Prostate Cancer

An Oral Androgen Receptor PROTAC® Degrader for Prostate Cancer

IHC and flow cytometry quantifies BRD4 levels in surrogate tissues after ex-vivo and in-vivo dosing with a BRD4 degrading PROTAC®

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells

Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
Menu
  • Careers
  • Privacy Policy
  • Terms of Use
Linkedin-in Twitter

© 2023 Arvinas. All rights reserved.

Arvinas logo
Search
Close
  • Our Science
    • PROTAC® Discovery Engine
    • Scientific Publications
    • Partnerships
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Research & Development
    • Pipeline
    • Androgen Receptor
    • Estrogen Receptor
    • Neuroscience
  • Careers & Culture
    • Open Positions
    • Life in New Haven
    • Our Values
    • Benefits
    • Giving Back
  • Patients
    • Patients with Breast Cancer
    • Patients with Prostate Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Menu
  • Contact Us
Linkedin-in Twitter
Skip to content